It has been shown that the activation of TLR9 by CpG activated pDCs, which were capable of initiating effective anti-tumor immunity through the activation of NK cells, mDCs and CD8+ T cells in a mouse melanoma model [14, 17–19]. This evidence concerns the gene CD8A and neoplasm.